MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
MyoKardia Inc at the Cowen and Company 38th Annual Health Care Conference (Replay)
March 13, 2018 at 9:20 a.m. ET
Recent Press Releases
03/08/18MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
NASDAQ GS | MYOK (Common Stock)
$49.95 + 1.30
03/19/1810:29 a.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.